Rhumbline Advisers boosted its position in Horizon Therapeutics Public Limited (NASDAQ:HZNP – Free Report) by 6.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 273,475 shares of the biopharmaceutical company’s stock after buying an additional 17,073 shares during the period. Rhumbline Advisers owned approximately 0.12% of Horizon Therapeutics Public worth $29,847,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also recently bought and sold shares of the company. Ieq Capital LLC boosted its position in Horizon Therapeutics Public by 6.6% in the first quarter. Ieq Capital LLC now owns 2,173 shares of the biopharmaceutical company’s stock valued at $237,000 after buying an additional 135 shares during the last quarter. Vanguard Personalized Indexing Management LLC boosted its position in Horizon Therapeutics Public by 0.7% in the 1st quarter. Vanguard Personalized Indexing Management LLC now owns 21,445 shares of the biopharmaceutical company’s stock worth $2,341,000 after purchasing an additional 141 shares in the last quarter. Xponance Inc. boosted its position in Horizon Therapeutics Public by 0.6% in the 1st quarter. Xponance Inc. now owns 28,757 shares of the biopharmaceutical company’s stock worth $3,139,000 after purchasing an additional 171 shares in the last quarter. First Republic Investment Management Inc. boosted its position in Horizon Therapeutics Public by 1.8% in the 2nd quarter. First Republic Investment Management Inc. now owns 10,142 shares of the biopharmaceutical company’s stock worth $809,000 after purchasing an additional 175 shares in the last quarter. Finally, Desjardins Global Asset Management Inc. boosted its position in Horizon Therapeutics Public by 7.6% in the 4th quarter. Desjardins Global Asset Management Inc. now owns 2,613 shares of the biopharmaceutical company’s stock worth $297,000 after purchasing an additional 185 shares in the last quarter. Hedge funds and other institutional investors own 80.37% of the company’s stock.
Wall Street Analyst Weigh In
HZNP has been the topic of several recent research reports. TheStreet lowered Horizon Therapeutics Public from a “b-” rating to a “c+” rating in a research report on Monday, May 8th. StockNews.com assumed coverage on Horizon Therapeutics Public in a research report on Thursday, August 17th. They issued a “buy” rating on the stock. Seven analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $110.71.
Horizon Therapeutics Public Trading Up 0.3 %
Shares of HZNP stock opened at $106.67 on Monday. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.27 and a quick ratio of 4.09. The company has a market cap of $24.43 billion, a price-to-earnings ratio of 57.04, a PEG ratio of 3.24 and a beta of 1.09. The stock has a 50 day simple moving average of $102.71 and a 200-day simple moving average of $105.77. Horizon Therapeutics Public Limited has a 1-year low of $57.84 and a 1-year high of $113.83.
Horizon Therapeutics Public (NASDAQ:HZNP – Get Free Report) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported $1.20 earnings per share for the quarter, beating analysts’ consensus estimates of $1.12 by $0.08. Horizon Therapeutics Public had a return on equity of 20.46% and a net margin of 12.02%. The company had revenue of $945.00 million for the quarter, compared to analyst estimates of $873.52 million. During the same quarter last year, the firm posted $1.07 EPS. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. On average, equities research analysts expect that Horizon Therapeutics Public Limited will post 4.7 EPS for the current fiscal year.
About Horizon Therapeutics Public
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation.
Featured Stories
- Five stocks we like better than Horizon Therapeutics Public
- What is the NASDAQ Stock Exchange?
- Ford Stock Skids Further into Value Territory
- How to Invest in the Best Canadian Stocks
- How Adobe’s Copyright Protection Will Make it an AI Leader
- The “How” and “Why” of Investing in 5G Stocks
- Marvell Shares Gap Down: Is AI Sentiment Changing?
Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.
